Correspondence 0001213900-24-099601 from Unicycive Therapeutics, Inc. (UNCY) (CIK 0001766140) (UNCY)
Unicycive Therapeutics, Inc. (UNCY) (CIK 0001766140)
Date: Nov. 18, 2024 · CIK: 0001766140 · Accession: 0001213900-24-099601
AI Filing Summary & Sentiment
File numbers found in text: 333-283210
Letter
Unicycive Therapeutics, Inc.
4300 El Camino Real, Suite 210
Los Altos, CA 94022
November 18, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Tim Buchmiller
Re: Unicycive Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-283210
Filed November 13, 2024
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Unicycive Therapeutics, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 5:00 p.m., Eastern Daylight Time, on Wednesday, November 20, 2024, or as soon thereafter as possible. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Please notify Jeffrey Fessler of Sheppard Mullin Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the registration statement has been declared effective pursuant to this acceleration request.
Very truly yours,
UNICYCIVE THERAPEUTICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
Unicycive Therapeutics, Inc.
4300 El Camino Real, Suite 210
Los Altos, CA 94022
November 18, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Tim Buchmiller
Re: Unicycive Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-283210
Filed November 13, 2024
Ladies and Gentlemen:
Pursuant to Rule 461 of the
General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Unicycive Therapeutics, Inc.
(the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated
so that it will become effective at 5:00 p.m., Eastern Daylight Time, on Wednesday, November 20, 2024, or as soon thereafter as possible.
In making this acceleration request, the Company acknowledges that it is aware of its responsibilities
under the Act.
Please notify Jeffrey Fessler
of Sheppard Mullin Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the registration
statement has been declared effective pursuant to this acceleration request.
Very truly yours,
UNICYCIVE THERAPEUTICS, INC.
By:
/s/ Shalabh Gupta
Name:
Shalabh Gupta
Title:
Chief Executive Officer
cc: Jeffrey Fessler, Sheppard Mullin Richter & Hampton LLP